| CEO Name | Paul J. Diaz |
| Nationality | United States |
| Net Worth Estimation | $25 million |
Paul J. Diaz's estimated net worth of around $25 million primarily stems from his executive compensation, stock awards, and performance incentives as CEO of Myriad Genetics, along with prior earnings from leadership roles at other healthcare companies. SEC filings and financial disclosures document his substantial stock ownership and salary, which directly contribute to his valuation.
Paul J. Diaz, CEO of Myriad Genetics, has an estimated net worth of $25,000,000, which is 21.4% of the maximum and 150% of the minimum estimated CEO net worth in the biotechnology category. His net worth is positioned towards the lower-middle range of comparable biotech CEOs.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Paul J. Diaz Performance in Myriad Genetics
Paul J. Diaz, CEO of Myriad Genetics, drives strategic decision-making focused on innovation in genetic testing and personalized medicine. His leadership has enhanced operational performance, expanding market presence and accelerating product development pipelines. Diaz's impact is evident in Myriad's strengthened competitive position and improved shareholder value under his tenure.
Latest News
Myriad Genetics Names Sam Raha CEO, Emphasizing Growth and Innovation
Sam Raha took over as President and CEO of Myriad Genetics in April 2025, succeeding Paul J. Diaz. Raha, previously COO, is leading Myriad with a focus on clinical diagnostics growth, including new AI-powered cancer tests and strategic collaborations like SOPHiA GENETICS for advanced liquid biopsy diagnostics, driving revenue and innovation in molecular diagnostics.
Source: http://www.investing.com/news/company-news/myriad-genetics-names-new-ceo-and-coo-for-future-growth-93CH-3887307